PST-611 / PulseSight Therapeutics - LARVOL DELTA

A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Eyevensys

New P1 trial • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD (GlobeNewswire) - "PulseSight Therapeutics...today announces the first close of its Series A financing with existing investor Pureos BioVentures committing new funds to support the Phase I study of PST-611 and enable preparation for a Phase IIa clinical trial....PST-611 is a first in class non-viral vectorized therapy for the treatment of dry age-related macular degeneration (AMD)/geographic atrophy (GA)...The planned PST-611-CT1 clinical trial aims at primarily confirming the favorable safety profile of PST-611 administration and is expected to start Q2 2025, subject to the regulatory greenlight, with readout anticipated end 2025/early 2026....The Series A financing remains open to new investors, to provide funds to support PST-611 Phase IIa clinical trial preparation and implementation, as well as the development of PulseSight’s wider portfolio of non-viral vectorized therapies including PST-809, a potential first-in-class therapy for wet AMD that comprises a dual-gene plasmid encoding..."

Financing • New P2a trial • P2a data • Regulatory • Dry Age-related Macular Degeneration • Ophthalmology

[VIRTUAL] Human transferrin protects retinal ganglion cells in a rat model of ocular hypertension (ARVO 2021) - "These results demonstrate the ability of Tf to protect RGCs exposed to elevated IOP, suggesting that iron chelation could benefit glaucoma patients. These proof-of-concept findings and previous data demonstrating sustained intraocular production of Tf following non-viral gene transfer strongly support the evaluation of EYS611 for long-term and effective neuroprotection in glaucoma."

Preclinical • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Glaucoma • Inherited Retinal Dystrophy • Macular Degeneration • Ocular Inflammation • Ophthalmology • Optic Neuritis • Retinal Disorders • Retinitis Pigmentosa • RBPMS